Financial Performance - Revenues for Q4 2024 were $13.1 million, up 4% from $12.6 million in Q4 2023, and full-year revenues reached $41.8 million, a 71% increase from $24.4 million in 2023[5][12] - Net income for Q4 2024 was $1.5 million, or $0.09 per diluted share, marking the fifth consecutive quarter of profitability, compared to $4.2 million, or $0.26 per diluted share, in Q4 2023[9][16] - Gross profit for Q4 2024 was $7.1 million, or 54.4% of revenues, down from $7.8 million, or 62.3% of revenues, in Q4 2023, primarily due to a one-time discount and higher service costs[7] - Adjusted EBITDA for Q4 2024 was $1.9 million, down from $5.7 million in Q4 2023, reflecting higher income tax expense in the prior year[10] - Gross profit for the year 2024 was $24,431,000, a significant increase from $14,060,000 in 2023, representing a growth of 73%[30] - Net income for Q4 2024 was $1,546,000, compared to $4,210,000 in Q4 2023, indicating a decrease of 63%[30] - Operating expenses for Q4 2024 totaled $5,381,000, significantly higher than $2,244,000 in Q4 2023, an increase of 140%[30] - The company reported a basic net income per share of $0.09 for Q4 2024, down from $0.26 in Q4 2023[30] Assets and Liabilities - Cash and cash equivalents at year-end 2024 were $22.1 million, with no debt, compared to $23.1 million in 2023[11] - Total current assets rose to $56,738,000 in 2024, up from $49,528,000 in 2023, reflecting an increase of 15%[31] - Accounts receivable increased significantly to $19,731,000 in 2024, compared to $10,645,000 in 2023, marking an increase of 85%[31] - Total liabilities increased to $6,338,000 in 2024 from $4,868,000 in 2023, representing a rise of 30%[31] - Retained earnings grew to $13,434,000 in 2024, up from $6,787,000 in 2023, indicating a growth of 98%[31] - Cash and cash equivalents decreased to $22,056,000 in 2024 from $23,148,000 in 2023, a decline of 5%[31] Product and Market Developments - A record 39 SRT systems were shipped in Q4 2024, representing an 18% increase year-over-year, with a total of 115 systems shipped for the year, up 74%[5][12] - The company plans to re-submit its TDI 510(k) application in the first half of 2025, indicating ongoing product innovation efforts[3] - The Fair Deal Agreement program is expected to contribute to revenues in the second half of 2025, with multiple new agreements in the pipeline[2] - The company anticipates that Q1 2025 sales could be considerably lower than Q1 2024, but expects full-year sales growth in 2025 compared to 2024[4] Research and Development - Research and development expenses for 2024 were $4.2 million, an increase of $0.5 million from 2023, driven by higher compensation and product development costs[15]

Company Performance - Sensus Healthcare, Inc. (SRTS) closed at $6.92, reflecting a +1.91% change from the previous day's close, outperforming the S&P 500's daily gain of 0.92% [1] - Over the past month, shares of the company have decreased by 5.3%, while the Medical sector gained 3.83% and the S&P 500 gained 0.81% [1] Upcoming Earnings - The company's earnings report is scheduled for February 5, 2025, with an expected EPS of $0.10, indicating a 61.54% decline from the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $9.86 million, down 21.6% from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Sensus Healthcare, Inc. are important for investors, as positive revisions can indicate a favorable business outlook [3] - The Zacks Rank system, which incorporates these estimate changes, provides a functional rating system for assessing stock performance [4] Zacks Rank and Valuation - Sensus Healthcare, Inc. currently holds a Zacks Rank of 3 (Hold), with the consensus EPS estimate remaining steady over the past month [5] - The company is trading at a Forward P/E ratio of 9.56, which is a discount compared to the industry average Forward P/E of 28.24 [6] Industry Context - The Medical - Instruments industry, to which Sensus Healthcare belongs, has a Zacks Industry Rank of 76, placing it in the top 31% of over 250 industries [6][7] - The Zacks Industry Rank assesses the strength of industry groups based on the average Zacks Rank of individual stocks, indicating that top-rated industries outperform lower-rated ones by a factor of 2 to 1 [7]

Company Performance - Sensus Healthcare reported third-quarter 2024 earnings of 7 cents per share, exceeding the Zacks Consensus Estimate of a loss of 2 cents per share by 450% [1] - The company's third-quarter revenue surpassed estimates by 51.3% [1] - Sensus Healthcare shares ended the last trading session 7.9% higher at $7.34, following an impressive trading volume [4] Stock Trends - The stock has experienced a 20.9% loss over the past four weeks prior to the recent increase [4] - The consensus EPS estimate for Sensus Healthcare has remained unchanged over the last 30 days, indicating a potential for future price movements [6] Industry Context - Sensus Healthcare operates within the Zacks Medical - Instruments industry [7] - Another company in the same industry, DexCom, closed the last trading session 0.4% higher at $80.57, with a 2.7% return over the past month [7]

Core Viewpoint - Sensus Healthcare, Inc. (SRTS) has shown a significant price increase of 31% over the past four weeks, with analysts projecting a mean price target of $11.67, indicating a potential upside of 36% from the current price of $8.58 [1] Price Target Analysis - The average price target for SRTS ranges from a low of $10 to a high of $14, with a standard deviation of $2.08, suggesting a variability in estimates. The lowest estimate indicates a 16.6% increase, while the highest suggests a 63.2% upside [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [7] Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism regarding SRTS's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [9] - The Zacks Consensus Estimate for the current year has increased by 13.9% over the past month, with two estimates rising and no negative revisions [10] - SRTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [11] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions. Analysts may set overly optimistic targets due to business incentives [5][6][8]

Financial Performance - Revenues for Q3 2024 were $8.8 million, a 127% increase from $3.9 million in Q3 2023, driven by higher superficial radiotherapy unit sales[2] - Net income for Q3 2024 was $1.2 million, or $0.07 per diluted share, compared to a net loss of $1.5 million, or $0.09 per share, in Q3 2023[9] - Adjusted EBITDA for Q3 2024 was $1.6 million, compared to negative $1.7 million in Q3 2023[9] - Revenues for the nine months ended September 30, 2024, were $28.7 million, a 143% increase from $11.8 million in the same period of 2023[11] - Revenues for Q3 2024 reached $8,839,000, a significant increase from $3,898,000 in Q3 2023, representing a growth of 126%[26] - Net income for Q3 2024 was $1,215,000, a recovery from a net loss of $1,451,000 in Q3 2023[26] Cash and Assets - The company exited Q3 2024 with $22.6 million in cash and cash equivalents, with no debt[10] - Total current assets increased to $54,806,000 as of September 30, 2024, up from $49,528,000 at the end of 2023[27] - Accounts receivable, net, rose to $16,961,000 in Q3 2024, compared to $10,645,000 in Q3 2023, reflecting improved sales collection[27] - Retained earnings grew to $11,888,000 as of September 30, 2024, up from $6,787,000 at the end of 2023, indicating stronger profitability retention[28] Expenses and Liabilities - Operating expenses for Q3 2024 totaled $3,745,000, a decrease from $3,884,000 in Q3 2023, showing cost management efforts[26] - Research and development expenses for Q3 2024 were $0.9 million, down from $1.1 million in Q3 2023[8] - Total liabilities increased to $5,727,000 as of September 30, 2024, from $4,868,000 at the end of 2023[28] Sales and Market Expansion - A total of 27 systems were shipped in Q3 2024, including one SRT-100 unit to an international customer, compared to 11 systems in Q3 2023[2] - The company signed a Fair Deal Agreement with Platinum Dermatology Partners, expanding access to SRT for patients across 130 clinics in the U.S.[3] Profitability Metrics - Gross profit for Q3 2024 was $5.2 million, or 59.3% of revenues, compared to $2.0 million, or 51.0% of revenues, in Q3 2023[6] - Gross profit for Q3 2024 was $5,240,000, compared to $1,989,000 in Q3 2023, indicating a gross margin improvement[26] Other Financial Metrics - The company reported interest income of $279,000 in Q3 2024, slightly up from $277,000 in Q3 2023[26] - The weighted average number of shares used in computing net income per share was 16,321,131 for Q3 2024, compared to 16,270,403 for Q3 2023[26] Market Overview - The market for non-melanoma skin cancer treatments is significant, with an estimated 70 million Americans affected during their lifetime[4]

Sensus Healthcare, Inc. (SRTS) closed the last trading session at $7.64, gaining 14.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $10.67 indicates a 39.7% upside potential.The average comprises three short-term price targets ranging from a low of $10 to a high of $12, with a standard deviation of $1.15. While the lowest estimate indicates an increase of 30.9% from the current ...

Core Viewpoint - The article emphasizes the importance of identifying and sustaining stock trends for successful short-term investing, highlighting the need for sound fundamentals and positive earnings estimates to maintain momentum [1]. Group 1: Stock Performance - Sensus Healthcare, Inc. (SRTS) has shown a solid price increase of 16.1% over the past 12 weeks, indicating investor confidence in its potential upside [3]. - The stock has also increased by 14.9% over the last four weeks, suggesting that the upward trend is still intact [4]. - SRTS is currently trading at 89.6% of its 52-week high-low range, indicating a potential breakout [4]. Group 2: Fundamental Strength - SRTS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting strong optimism from the brokerage community regarding its near-term price performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like SRTS that are on an upward trend supported by strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to find stocks that align with their personal investing styles [7].

This revised news release replaces the one issued on November 14, 2024, contains several non-financial changes throughout and removes the name of and references to a new customer, at the customer’s request. The agreement with the new customer remains in effect. Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a non-GAAP measure) of $1.6 million compares with negative $1.7 million a year ago Expects to have more than 50 IG-SRT Systems signed under the Fair Deal A ...

Sensus Healthcare (NASDAQ: SRTS ) is a company that develops equipment to treat skin problems, including non-melanoma cancer. I had previously covered the company in which I commented that the initiatives to generate recurring revenue wereMy name is María Fernanda and I am currently studying an MBA. My inspiration investors are Warren Buffett, Peter Lynch and Terry Smith, so I look for quality companies at a reasonable valuation. I believe that, in the long term, fundamentals are what drive the share price, ...

Sensus Healthcare, Inc. (NASDAQ:SRTS) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Kim Golodetz - Alliance Advisors IR Joseph Sardano - Chairman and CEO Michael Sardano - President and General Counsel Javier Rampolla - CFO Conference Call Participants Jason Wittes - ROTH Anthony Vendetti - Maxim Ilya Zubkov - Freedom Broker Jade Montgomery - H.C. Wainwright Operator Good afternoon and welcome to the Sensus Healthcare Third Quarter 2024 Financial Results Conference Call. ...